Latest news

Filter by category:

FILTER: ALL CATEGORIESFilter by:

Latest news

25 Nov 2022

Scientists take aim at next pandemic threat with new molecular clamp rapid-response vaccine platform
Vaccine platform holds promise for the rapid development of vaccines against future infectious disease epidemics, potentially within 100 days of a new virus emerging

Read more

Read article

09 Nov 2022

From SpillOver to Disease X: new AI collaboration aims to rank viral families with greatest pandemic threat
CEPI to provide US$1.76 million to support application of AI to expand UC Davis' SpillOver database

Read more

09 Nov 2022

Climate change isn’t just warming the planet, it’s increasing spillover risks and pandemic threats
Expert calls for more investment to prevent viral spillover at source to mitigate against pandemic threats

Read more

03 Nov 2022

Global health agencies outline plan to support Ugandan Government-led response to outbreak of Ebolavirus disease
JOINT STATEMENT BY CEPI-GAVI-WHO

Read more

03 Nov 2022

CEPI Publishes Independent Outcome Evaluation of CEPI 1.0
CEO Dr Richard Hatchett reflects on the final report of an independent evaluation of CEPI's first five-year business cycle (2017-2021)

Read more

25 Oct 2022

CEPI and SK bioscience partner to advance mRNA vaccine technology to build vaccine library, enable rapid response against Disease X
Up to $40 million in funding committed to support development of mRNA-vaccine candidates against Lassa Fever virus and Japanese Encephalitis virus

Read more

22 Oct 2022

Lassa fever experts gather in Abuja for workshop hosted by CEPI and Nigeria CDC to advance Lassa research
Set up and funded by CEPI, Enable aims to provide a more detailed description of the epidemiology of Lassa fever in West Africa

Read more

12 Oct 2022

As CEPI ramps up vaccine research, a new study warns Lassa fever is set to expand its reach across Africa
Climate change and other environmental factors could cause Lassa fever to spread. CEPI is the leading funder of research into vaccines against the potentially deadly virus.

Read more

Read article

10 Oct 2022

Rift Valley fever: What’s next for the climate-driven disease with epidemic potential?
A Q+A with CEPI Vaccine R&D Project Leader, Mike Whelan, discussing the characteristics of the disease and CEPI's new call with the European Union to advance Rift Valley fever vaccines.

Read more

06 Oct 2022

CEPI partners with Intravacc to develop an intranasal, broadly protective Betacoronavirus vaccine
The Avacc 101 vaccine candidate will be designed to provide broad protection against SARS-CoV-1, SAR-CoV-2, and MERS-CoV

Read more

16 Sep 2022

Rift Valley fever vaccines to advance with new $50 million CEPI and EU funding call
Up to USD 50m (EUR 50m) will be provided to vaccine projects, with support from the European Union’s Horizon Europe programme.

Read more

©2022 CEPI. All rights reserved